novel
reassort
avian
influenza
viru
emerg
human
eastern
china
late
februari
viru
strain
resist
adamantan
amantadin
rimantadin
suscept
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
one
strain
contain
substitut
neuraminidas
na
gene
indic
resist
oseltamivir
pyrosequenc
proven
use
tool
surveil
drug
resist
influenza
virus
describ
revers
transcript
rt
pcr
assay
coupl
pyrosequenc
identifi
na
residu
number
virus
total
specimen
clinic
sampl
isol
test
one
isol
contain
heterogen
mutat
detect
pyrosequenc
confirm
sanger
sequenc
howev
mutat
detect
origin
clinic
specimen
sinc
viru
isol
might
lead
select
variant
might
fulli
repres
viru
popul
clinic
specimen
suggest
use
pyrosequenc
detect
nai
resist
virus
directli
clinic
specimen
rather
cultur
isol
crossreact
type
influenza
viru
respiratori
tract
virus
found
assay
sensit
copi
synthet
rna
three
codon
high
sensit
specif
assay
suffici
detect
posit
clinic
specimen
studi
provid
rapid
reliabl
method
character
nai
resist
virus
new
type
avian
influenza
emerg
begin
sever
provinc
eastern
china
sinc
first
report
case
shanghai
total
confirm
avian
influenza
infect
human
report
includ
death
februari
may
world
health
organ
case
progress
rapidli
accompani
acut
respiratori
distress
syndrom
mediastin
emphysema
septic
shock
result
disturb
conscious
acut
kidney
injuri
virus
previous
report
infect
human
infect
pathogen
avian
influenza
virus
includ
previous
report
china
part
world
chan
cheng
et
al
fouchier
et
al
ostrowski
et
al
tweed
et
al
sinc
viru
novel
avianorigin
reassort
influenza
viru
gao
et
al
without
effect
vaccin
antivir
drug
provid
valuabl
option
earli
contain
highli
virul
andor
novel
strain
current
two
class
drug
adamantan
channel
blocker
neuraminidas
inhibitor
nai
zanamivir
oseltamivir
avail
treatment
influenza
infect
nguyen
et
al
howev
drugresist
influenza
virus
report
emerg
global
spread
adamantineresist
virus
bright
et
al
oseltamivirresist
season
virus
dharan
et
al
sinc
pandem
influenza
virus
found
gener
resist
adamantin
nguyen
et
al
fortun
nai
resist
rare
detect
virus
graitcer
et
al
oseltamivirresist
mutant
common
due
rapid
develop
resist
compar
zanamivir
okomoadhiambo
et
al
recent
mutat
reduc
sensit
zanamivir
oseltamivir
detect
virus
isol
patient
previous
treat
nai
dapat
et
al
although
sever
class
antiinfluenza
compound
exist
nai
current
option
clinic
set
moscona
center
diseas
control
prevent
atlanta
ga
usa
recommend
confirm
probabl
case
infect
investig
treat
nai
oseltamivir
zanamivir
earli
possibl
due
potenti
sever
ill
associ
viru
infect
center
diseas
control
prevent
cdc
among
oseltamivirresist
virus
commonli
detect
substitut
number
subtyp
dharan
et
al
graitcer
et
al
virus
subtyp
ferrari
lina
hurt
et
al
sheu
et
al
type
b
virus
ferrari
lina
recent
one
cultur
viru
isol
found
contain
substitut
posit
number
posit
number
na
protein
gao
et
al
patient
treat
oseltamivir
mutat
subsequ
detect
two
patient
indic
may
low
barrier
develop
drug
resist
patient
treat
oseltamivir
howev
increas
surveil
oseltamivir
suscept
urgent
requir
recent
nucleotidebas
assay
pyrosequenc
develop
detect
nairesistanceconf
mutat
compar
convent
sanger
sequenc
method
pyrosequenc
identifi
establish
resistanceconf
substitut
much
rapidli
addit
assay
use
directli
clinic
specimen
nasal
oropharyng
swab
studi
describ
assay
use
revers
transcript
rt
pcr
coupl
pyrosequenc
procedur
rtpcrpyroseq
detect
na
residu
number
virus
advantag
assay
includ
rapid
analysi
simplic
eas
use
provid
direct
result
character
oseltamivir
resist
virus
heterogen
mutant
isol
femal
resid
wuxi
citi
jiangsu
provinc
admit
wuxi
citi
peopl
hospit
due
cough
highest
temperatur
reach
c
march
chest
radiographi
show
pneumonia
upper
lobe
left
lung
march
march
throat
swab
sputum
sent
laboratori
jiangsu
center
diseas
control
prevent
jscdc
test
rtpcr
result
reveal
presenc
avian
influenza
viru
meanwhil
laboratori
test
pathogen
includ
influenza
viru
influenza
b
viru
coronaviru
neg
specimen
viraltransport
medium
inocul
madindarbi
canin
kidney
mdck
cell
viru
isol
march
includ
two
three
blind
passag
oral
oseltamivir
mg
administ
twice
daili
begin
march
march
patient
transfer
intens
care
unit
icu
unfortun
patient
die
acut
respiratori
distress
syndrom
april
twentysix
origin
clinic
sampl
throat
swab
sputum
jiangsu
china
collect
jscdc
februari
april
collect
patient
treatment
oseltamivir
specimen
first
propag
allanto
caviti
specif
pathogenfre
embryon
chicken
egg
virus
success
propag
egg
cultur
mdck
cell
jscdc
total
viral
isol
embryon
chicken
egg
seven
isol
mdck
cell
success
collect
project
approv
ethic
committe
jiangsu
provinci
center
diseas
prevent
control
written
inform
consent
obtain
particip
viral
rna
isol
clinic
sampl
extract
nucleic
acid
extract
kit
qiasymphoni
virusbacteria
mini
kit
qiagen
germani
magna
pure
tm
system
roch
appli
scienc
germani
accord
manufactur
instruct
rtpcr
perform
specimen
use
superscript
iii
platinum
onestep
quantit
rtpcr
kit
invitrogen
usa
abi
realtim
pcr
system
abi
usa
issu
primer
probe
accord
recommend
protocol
world
health
organ
sampl
posit
pcr
result
cycl
threshold
ct
valu
influenza
target
na
sequenc
virus
use
templat
studi
obtain
genbank
databas
access
number
primer
design
use
pyrosequen
assay
design
softwar
qiagen
sweden
align
sequenc
human
avian
influenza
viru
isol
acquir
genbank
influenza
sequenc
databas
primer
synthes
sangon
biotech
co
china
tabl
show
list
rtpcr
pyrosequenc
primer
use
studi
rtpcr
amplif
perform
use
onestep
rtpcr
kit
qiagen
germani
primer
tabl
ad
concentr
standard
l
reaction
volum
rtpcr
protocol
follow
c
min
c
min
follow
cycl
c
c
c
confirm
result
rtpcr
product
visual
use
qiaxcel
system
qiagen
germani
dna
fragment
analysi
one
pcr
primer
biotinyl
captur
streptavidinco
sepharos
bead
ge
healthcar
usa
incub
room
temperatur
minut
agit
rpm
singlestrand
dna
obtain
wash
immobil
pcr
product
etoh
tabl
rtpcr
sequenc
primer
use
studi
sequenc
denatur
naoh
wash
wash
buffer
use
vacuum
prep
tool
vacuum
prep
worktabl
qiagen
germani
bead
suspend
l
anneal
buffer
contain
sequenc
primer
singlestrand
dna
hybrid
sequenc
primer
incub
c
min
room
temperatur
min
prime
singlestrand
pcr
product
sequenc
use
psqtm
system
qiagen
germani
sequenc
reaction
perform
psq
reagent
kit
qiagen
germani
consensu
preprogram
dispens
order
determin
integr
sequenc
inform
strain
given
sequenc
site
detect
antivir
suscept
na
posit
virus
accord
manufactur
protocol
sampl
run
duplic
rtpcrpyroseq
posit
sampl
contain
resist
codon
confirm
sanger
sequenc
sanger
sequenc
na
residu
sanger
sequenc
employ
verifi
result
one
isol
contain
mutat
match
clinic
sampl
rtpcr
amplicon
pyrosequenc
cycl
sequenc
use
bigdy
termin
reaction
kit
abi
usa
abi
autom
dna
sequenc
dna
analyz
determin
sensit
assay
detect
mutat
oseltamivirresist
codon
gta
tat
aag
particularli
appear
mix
popul
drugsensit
drugresist
quasispeci
five
na
plasmid
genescript
china
one
wildtyp
contain
cat
agg
codon
one
wildtyp
contain
gaa
codon
three
mutat
contain
tat
aag
gta
codon
construct
respect
viral
rna
transcript
na
gene
amplifi
plasmid
primer
contain
promot
sequenc
revers
side
vitro
transcrib
rna
polymeras
takara
china
accord
manufactur
instruct
synthet
rna
transcript
purifi
quantifi
mix
equalmolar
amount
dilut
serial
final
concentr
rna
copi
per
assay
synthet
rna
transcript
also
adjust
defin
mixtur
respect
amplifi
pyrosequenc
evalu
specif
rtpcrpyroseq
procedur
isol
season
influenza
influenza
type
b
parainfluenza
virus
type
human
coronavirus
respiratori
syncyti
virus
rhinovirus
test
use
rtpcrpyroseq
method
amplifi
target
bp
na
gene
fragment
contain
codon
specimen
rtpcr
residu
detect
clinic
sampl
isol
rtpcrpyroseq
method
histidin
tyrosin
mutat
na
residu
cat
tat
virus
report
confer
resist
oseltamivir
deyd
et
al
le
et
al
pyrosequenc
result
show
histidin
cat
residu
posit
sampl
fig
amplicon
gener
primer
set
biot
repres
biotin
also
use
dna
templat
analyz
chang
residu
known
confer
resist
oseltamivir
previou
studi
report
arginin
agg
lysin
aag
mutat
one
isol
gao
et
al
two
patient
oseltamivir
therapi
howev
find
mutat
sampl
collect
jiangsu
provinc
pyrosequenc
result
show
wildtyp
sequenc
agg
arginin
codon
fig
challeng
design
univers
set
pyrosequenc
primer
three
codon
interest
name
virus
sinc
distant
other
amplicon
gener
primer
set
tabl
use
dna
templat
analyz
chang
residu
known
confer
resist
oseltamivir
rtpcr
success
amplifi
target
bp
na
gene
fragment
contain
codon
specimen
posit
number
posit
number
substitut
gaa
gta
na
gene
virus
report
confer
resist
oseltamivir
okomoadhiambo
et
al
studi
result
pyrosequenc
assay
show
one
viral
isol
patient
describ
propag
one
gener
mdck
cell
sequenc
gtaa
fig
investig
isol
rtpcr
product
test
sanger
sequenc
result
reveal
mix
nucleotid
ta
code
amino
acid
posit
fig
indic
glutam
acid
gaa
partial
replac
valin
gta
highthroughput
illumina
miseq
sequenc
result
also
confirm
differenti
mix
popul
gaa
gta
posit
na
gene
show
gluval
ratio
cultur
viru
popul
data
shown
interestingli
heterogen
mutant
detect
match
clinic
specimen
use
either
pyrosequenc
fig
sanger
sequenc
fig
clinic
sampl
detect
wildtyp
gaa
suggest
variant
present
low
proport
clinic
specimen
analyt
sensit
rtpcrpyroseq
assay
assess
use
serial
dilut
synthet
viral
rna
transcript
result
demonstr
assay
detect
limit
copi
synthet
rna
six
codon
tabl
evalu
pyrosequenc
reveal
variant
mixtur
detect
rna
copi
rang
result
demonstr
detect
limit
minor
variant
mix
popul
drugsensit
resist
quasispeci
cyclic
dispens
order
gtca
gact
gtac
use
detect
na
variant
fig
show
repres
pyrosequenc
result
polymorph
differenti
mixtur
assess
specif
assay
season
influenza
influenza
type
b
parainfluenza
virus
type
human
coronavirus
respiratori
syncyti
virus
rhinovirus
test
posit
result
obtain
viral
rna
extract
describ
indic
assay
high
specif
monitor
suscept
influenza
virus
antiinfluenza
drug
especi
nai
critic
sinc
virus
resist
adamantan
gao
et
al
nai
commonli
oseltamivir
advoc
mani
countri
use
fig
detect
use
primer
cyclic
dispens
order
gtac
pyrogram
sequenc
result
residu
highlight
sequenc
gtaa
red
color
indic
glutam
acid
gaa
partli
replac
valin
gta
specimen
isol
mdck
cell
sanger
sequenc
result
show
mix
nucleotid
ta
code
amino
acid
posit
highlight
specimen
b
pyrogram
sequenc
result
residu
highlight
repres
oseltamivirsuscept
codon
gaa
red
color
c
sanger
sequenc
result
show
gaa
code
amino
acid
posit
origin
clinic
specimen
letter
list
peak
panel
nucleotid
dispens
pyrosequenc
pyromark
id
system
interpret
refer
color
figur
legend
reader
refer
web
version
articl
influenza
season
widespread
use
nai
caus
emerg
drugresist
virus
becom
seriou
public
health
problem
exampl
hu
et
al
report
mutat
na
gene
confer
resist
nai
identifi
two
patient
infect
virus
antivir
treatment
studi
demonstr
rapid
highthroughput
pyrosequenc
method
could
use
reliabl
detect
sequenc
associ
antivir
suscept
posit
virus
importantli
neither
mutat
detect
clinic
specimen
previou
studi
observ
emerg
two
nairesist
variant
influenza
viru
either
valin
isoleucin
posit
number
oseltamivirtr
immunocompromis
child
okomoadhiambo
et
al
simon
et
al
studi
one
cultur
viru
isol
patient
describ
heterogen
mutat
detect
pyrosequenc
method
highthroughput
sequenc
data
show
gluval
ratio
viru
popul
unpublish
data
unfortun
receiv
clinic
sampl
prior
commenc
oseltamivir
therapi
heterogen
mutat
detect
isol
day
oseltamivir
treatment
howev
mutat
detect
origin
clinic
specimen
use
either
sanger
sequenc
pyrosequenc
studi
provid
evid
although
heterogen
mutat
shown
emerg
follow
oseltamivir
treatment
detect
could
limit
viru
isol
propag
mdck
cell
viru
variant
may
appar
growth
advantag
wildtyp
virus
phenomenon
though
clearli
understood
could
consequ
differ
requir
na
activ
viru
replic
occur
cell
cultur
versu
human
host
okomoadhiambo
et
al
pyrosequenc
method
develop
studi
detect
limit
minor
variant
viru
carri
mutat
proport
level
detect
fals
neg
result
may
occur
assay
sensit
techniqu
molecular
clone
may
need
detect
minor
viru
variant
clinic
specimen
sinc
viru
isol
might
lead
select
mutant
virus
might
fulli
repres
viru
popul
clinic
specimen
detect
nai
resist
among
clinic
specimen
avian
influenza
viru
avoid
cultureinduc
heterogen
mutat
mutat
virus
rna
genom
errorpron
polymeras
influenza
virus
identifi
frequent
among
isol
obtain
viru
propag
cell
cultur
compar
primari
clinic
specimen
suggest
viru
replic
tissu
cultur
lead
select
variant
alter
receptor
specif
devri
et
al
exampl
mutat
na
gene
detect
cultur
virus
match
clinic
specimen
influenza
virus
okomoadhiambo
et
al
howev
definit
clear
whether
mutat
aris
passag
would
irrespect
cell
cultur
whether
mutat
select
driven
specif
cell
system
use
gener
quasispeci
also
occur
infect
individu
suggest
mutat
aris
viru
replic
laur
andino
therefor
import
perform
molecular
test
influenza
virus
match
clinic
viru
isol
obtain
sampl
date
emphas
although
clinic
resist
nai
conclus
establish
pyrosequenc
assay
present
studi
provid
reliabl
tool
rapid
highthroughput
detect
viral
variant
epidem
pandem
outbreak
influenza
compar
sanger
sequenc
pyrosequenc
less
expens
timeconsum
determin
sequenc
associ
nai
resist
virus
addit
pyrosequenc
system
builtin
align
capabl
make
sequenc
analysi
simpler
assay
sensit
copi
synthet
rna
three
codon
tabl
sensit
specif
assay
suffici
detect
posit
clinic
specimen
conclus
time
determin
drug
suscept
critic
order
make
inform
decis
antivir
usag
control
influenza
viru
infect
pyrosequenc
provid
highthroughput
rapid
platform
directli
detect
nai
resist
virus
without
extens
sampl
prepar
declar
conflict
interest
